4k9w › Citations

Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues.

Sevrioukova IF, Poulos TL
Biochemistry 52 4474-81 (2013)
Related entries: 4k9t, 4k9u, 4k9v, 4k9x

Cited: 50 times
EuropePMC logo PMID: 23746300

Abstract

Cytochrome P450 3A4 (CYP3A4) inhibitors ritonavir and cobicistat, currently administered to HIV patients as pharmacoenhancers, were designed on the basis of the chemical structure/activity relationships rather than the CYP3A4 crystal structure. To better understand the structural basis for CYP3A4 inhibition and the ligand binding process, we investigated five desoxyritonavir analogues to elucidate how substitution/elimination of the phenyl side groups (Phe-1 and Phe-2) and removal of the isopropyl-thiazole (IPT) moiety affect affinity, inhibitory potency, and the ligand binding mode. Our experimental and structural data indicate that the side group size reduction not only drastically lowers affinity and inhibitory potency for CYP3A4 but also leads to multiple binding modes. Regardless of the side group chemical nature and the number of molecules bound, the space adjacent to the 369-371 peptide and Arg105 (Phe-2 site) is always occupied and, hence, must be a critically important binding site. When possible, the ligands also try to fill the pocket near the I-helix (Phe-1 site), even if it causes steric hindrance. Extensive hydrophobic interactions established at the Phe-1 site improve inhibitory potency, whereas contacts provided by IPT might strengthen the Fe-N bond. Overall, however, the end group contributes less to the ligand association process, which, in contrast, is greatly facilitated by the polar interactions mediated by the active site Ser119.

Reviews - 4k9w mentioned but not cited (1)

  1. Current Approaches for Investigating and Predicting Cytochrome P450 3A4-Ligand Interactions. Sevrioukova IF, Poulos TL. Adv Exp Med Biol 851 83-105 (2015)

Articles - 4k9w mentioned but not cited (12)

  1. Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents. Zhang YK, Zhang H, Zhang GN, Wang YJ, Kathawala RJ, Si R, Patel BA, Xu J, Chen ZS. Oncotarget 6 24277-24290 (2015)
  2. High-Level Production and Properties of the Cysteine-Depleted Cytochrome P450 3A4. Sevrioukova IF. Biochemistry 56 3058-3067 (2017)
  3. Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study. Su J, Chang C, Xiang Q, Zhou ZW, Luo R, Yang L, He ZX, Yang H, Li J, Bei Y, Xu J, Zhang M, Zhang Q, Su Z, Huang Y, Pang J, Zhou SF. Drug Des Devel Ther 8 2555-2602 (2014)
  4. Identification of the Metabolic Enzyme Involved Morusin Metabolism and Characterization of Its Metabolites by Ultraperformance Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (UPLC/Q-TOF-MS/MS). Shi X, Mackie B, Zhang G, Yang S, Song Y, Su D, Liu Y, Shan L. Evid Based Complement Alternat Med 2016 9240103 (2016)
  5. Molecular Dynamics Simulation Framework to Probe the Binding Hypothesis of CYP3A4 Inhibitors. Kiani YS, Ranaghan KE, Jabeen I, Mulholland AJ. Int J Mol Sci 20 E4468 (2019)
  6. Four Major Channels Detected in the Cytochrome P450 3A4: A Step toward Understanding Its Multispecificity. Benkaidali L, André F, Moroy G, Tangour B, Maurel F, Petitjean M. Int J Mol Sci 20 E987 (2019)
  7. Homotropic Cooperativity of Midazolam Metabolism by Cytochrome P450 3A4: Insight from Computational Studies. Li J, Chen Y, Tang Y, Li W, Tu Y. J Chem Inf Model 61 2418-2426 (2021)
  8. Cytochrome P450 and P-gp Mediated Herb-Drug Interactions and Molecular Docking Studies of Garcinol. Bolla L, Srivastava P, Ravichandiran V, Nanjappan SK. Membranes (Basel) 11 992 (2021)
  9. Mechanistic Insights into the Regio- and Stereoselectivities of Testosterone and Dihydrotestosterone Hydroxylation Catalyzed by CYP3A4 and CYP19A1. Li J, Tang Y, Li W, Tu Y. Chemistry 26 6214-6223 (2020)
  10. Metabolism and Metabolic Inhibition of Xanthotoxol in Human Liver Microsomes. Ma Z, Shi X, Zhang G, Guo F, Shan L, Cai J. Evid Based Complement Alternat Med 2016 5416509 (2016)
  11. The Development of Target-Specific Pose Filter Ensembles To Boost Ligand Enrichment for Structure-Based Virtual Screening. Xia J, Hsieh JH, Hu H, Wu S, Wang XS. J Chem Inf Model 57 1414-1425 (2017)
  12. Unraveling the Abnormal Molecular Mechanism of Suicide Inhibition of Cytochrome P450 3A4. Zhou Y, Li J, Baryshnikov G, Tu Y. J Chem Inf Model 62 6172-6181 (2022)


Reviews citing this publication (8)

  1. Recent Structural Insights into Cytochrome P450 Function. Guengerich FP, Waterman MR, Egli M. Trends Pharmacol Sci 37 625-640 (2016)
  2. Structure-based ligand design to overcome CYP inhibition in drug discovery projects. Brändén G, Sjögren T, Schnecke V, Xue Y. Drug Discov Today 19 905-911 (2014)
  3. Cytochrome P450 structure-function: insights from molecular dynamics simulations. Nair PC, McKinnon RA, Miners JO. Drug Metab Rev 48 434-452 (2016)
  4. Thiazole Ring-A Biologically Active Scaffold. Petrou A, Fesatidou M, Geronikaki A. Molecules 26 3166 (2021)
  5. Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism. Sevrioukova IF, Poulos TL. Curr Top Med Chem 14 1348-1355 (2014)
  6. Alternative Splicing in the Cytochrome P450 Superfamily Expands Protein Diversity to Augment Gene Function and Redirect Human Drug Metabolism. Annalora AJ, Marcus CB, Iversen PL. Drug Metab Dispos 45 375-389 (2017)
  7. CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design. Das A, Weigle AT, Arnold WR, Kim JS, Carnevale LN, Huff HC. Pharmacol Ther 215 107601 (2020)
  8. Recyclization of Maleimides by Binucleophiles as a General Approach for Building Hydrogenated Heterocyclic Systems. Vandyshev DY, Shikhaliev KS. Molecules 27 5268 (2022)

Articles citing this publication (29)

  1. Mechanisms of Cytochrome P450-Catalyzed Oxidations. Guengerich FP. ACS Catal 8 10964-10976 (2018)
  2. Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model. Kaur P, Chamberlin AR, Poulos TL, Sevrioukova IF. J Med Chem 59 4210-4220 (2016)
  3. Mechanism of drug-drug interactions mediated by human cytochrome P450 CYP3A4 monomer. Denisov IG, Grinkova YV, Baylon JL, Tajkhorshid E, Sligar SG. Biochemistry 54 2227-2239 (2015)
  4. The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5. Hsu MH, Savas U, Johnson EF. Mol Pharmacol 93 14-24 (2018)
  5. Conformational selection dominates binding of steroids to human cytochrome P450 17A1. Guengerich FP, Wilkey CJ, Glass SM, Reddish MJ. J Biol Chem 294 10028-10041 (2019)
  6. Membrane Fluidity Modulates Thermal Stability and Ligand Binding of Cytochrome P4503A4 in Lipid Nanodiscs. McClary WD, Sumida JP, Scian M, Paço L, Atkins WM. Biochemistry 55 6258-6268 (2016)
  7. Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines. Horley NJ, Beresford KJ, Chawla T, McCann GJ, Ruparelia KC, Gatchie L, Sonawane VR, Williams IS, Tan HL, Joshi P, Bharate SS, Kumar V, Bharate SB, Chaudhuri B. Eur J Med Chem 129 159-174 (2017)
  8. The use of isomeric testosterone dimers to explore allosteric effects in substrate binding to cytochrome P450 CYP3A4. Denisov IG, Mak PJ, Grinkova YV, Bastien D, Bérubé G, Sligar SG, Kincaid JR. J Inorg Biochem 158 77-85 (2016)
  9. Concurrent cooperativity and substrate inhibition in the epoxidation of carbamazepine by cytochrome P450 3A4 active site mutants inspired by molecular dynamics simulations. Müller CS, Knehans T, Davydov DR, Bounds PL, von Mandach U, Halpert JR, Caflisch A, Koppenol WH. Biochemistry 54 711-721 (2015)
  10. Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Terelius Y, Figler RA, Marukian S, Collado MS, Lawson MJ, Mackey AJ, Manka D, Qualls CW, Blackman BR, Wamhoff BR, Dash A. Chem Biol Interact 255 31-44 (2016)
  11. Editorial Antiretroviral boosting by cobicistat, a structural analog of ritonavir. Greenblatt DJ. Clin Pharmacol Drug Dev 3 335-337 (2014)
  12. Dissecting the Cytochrome P450 1A2- and 3A4-Mediated Metabolism of Aflatoxin B1 in Ligand and Protein Contributions. Bonomo S, Jørgensen FS, Olsen L. Chemistry 23 2884-2893 (2017)
  13. Inhibition of Human CYP3A4 by Rationally Designed Ritonavir-Like Compounds: Impact and Interplay of the Side Group Functionalities. Samuels ER, Sevrioukova I. Mol Pharm 15 279-288 (2018)
  14. Structure-Activity Relationships of Rationally Designed Ritonavir Analogues: Impact of Side-Group Stereochemistry, Headgroup Spacing, and Backbone Composition on the Interaction with CYP3A4. Samuels ER, Sevrioukova I. Biochemistry 58 2077-2087 (2019)
  15. Structural Perspectives of the CYP3A Family and Their Small Molecule Modulators in Drug Metabolism. Wright WC, Chenge J, Chen T. Liver Res 3 132-142 (2019)
  16. 7,8-benzoflavone binding to human cytochrome P450 3A4 reveals complex fluorescence quenching, suggesting binding at multiple protein sites. Marsch GA, Carlson BT, Guengerich FP. J Biomol Struct Dyn 36 841-860 (2018)
  17. An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4. Samuels ER, Sevrioukova IF. Bioorg Med Chem 28 115349 (2020)
  18. Bioactivation and Regioselectivity of Pig Cytochrome P450 3A29 towards Aflatoxin B₁. Wu J, Chen R, Zhang C, Li K, Xu W, Wang L, Chen Q, Mu P, Jiang J, Wen J, Deng Y. Toxins (Basel) 8 E267 (2016)
  19. 4-(Indol-3-yl)thiazole-2-amines and 4-ιndol-3-yl)thiazole Acylamines as Νovel Antimicrobial Agents: Synthesis, In Silico and In Vitro Evaluation. Simakov S, Kartsev V, Petrou A, Nicolaou I, Geronikaki A, Ivanov M, Kostic M, Glamočlija J, Soković M, Talea D, Vizirianakis IS. Pharmaceuticals (Basel) 14 1096 (2021)
  20. Functioning of drug-metabolizing microsomal cytochrome P450s: In silico probing of proteins suggests that the distal heme 'active site' pocket plays a relatively 'passive role' in some enzyme-substrate interactions. Venkatachalam A, Parashar A, Manoj KM. In Silico Pharmacol 4 2 (2016)
  21. Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5. Wang J, Buchman CD, Seetharaman J, Miller DJ, Huber AD, Wu J, Chai SC, Garcia-Maldonado E, Wright WC, Chenge J, Chen T. J Am Chem Soc 143 18467-18480 (2021)
  22. High-throughput functional screening of steroid substrates with wild-type and chimeric P450 enzymes. Urban P, Truan G, Pompon D. Biomed Res Int 2014 764102 (2014)
  23. N-Heterocyclic Carbene Capture by Cytochrome P450 3A4. Jennings GK, Ritchie CM, Shock LS, Lyons CE, Hackett JC. Mol Pharmacol 90 42-51 (2016)
  24. The Cytochrome P450 3A4 has three Major Conformations: New Clues to Drug Recognition by this Promiscuous Enzyme. Benkaidali L, André F, Moroy G, Tangour B, Maurel F, Petitjean M. Mol Inform 36 (2017)
  25. Crystal Structure of CYP3A4 Complexed with Fluorol Identifies the Substrate Access Channel as a High-Affinity Ligand Binding Site. Sevrioukova IF. Int J Mol Sci 23 12591 (2022)
  26. Discovery of 5-Methylthiazole-Thiazolidinone Conjugates as Potential Anti-Inflammatory Agents: Molecular Target Identification and In Silico Studies. Haroun M, Petrou A, Tratrat C, Kolokotroni A, Fesatidou M, Zagaliotis P, Gavalas A, Venugopala KN, Sreeharsha N, Nair AB, Elsewedy HS, Geronikaki A. Molecules 27 8137 (2022)
  27. Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment. Samuels ER, Sevrioukova IF. Int J Mol Sci 23 7291 (2022)
  28. Selective steroidogenic cytochrome P450 haem iron ligation by steroid-derived isonitriles. Richard AM, Wong NR, Harris K, Sundar R, Scott EE, Pochapsky TC. Commun Chem 6 183 (2023)
  29. Structural characterization of the homotropic cooperative binding of azamulin to human cytochrome P450 3A5. Hsu MH, Johnson EF. J Biol Chem 298 101909 (2022)


Quick links